Found 3 articles for: "Tapinarof"
Treatment of Granuloma Annulare Using Tapinarof Cream 1%
October 2024 | Volume 23 | Issue 10 | Case Reports | 889 | Copyright © October 2024
Granuloma annulare is a benign, non-infectious cutaneous granulomatous disease. Its pathogenesis is not completely elucidatedbut has recently been thought to involve immunologic and ...
Read MoreA Review of Tapinarof: Novel Topical Treatment for Plaque Psoriasis in Adults
August 2023 | Volume 22 | Issue 8 | Original Article | 761 | Copyright © August 2023
Psoriasis is a chronic, immune-mediated, multisystem, inflammatory dermatological condition that is persistent and relapsing. Topical treatments are first line agents for mild to moderate plaque ...
Read MoreDermal Safety of Tapinarof Cream 1%: Results From 4 Phase 1 Trials
October 2022 | Volume 21 | Issue 10 | Original Article | 1084 | Copyright © October 2022
Background: Tapinarof (VTAMA®; Dermavant Sciences, Inc.) is a novel, non-steroidal, topical, aryl hydrocarbon receptor agonist, FDA approved for psoriasis treatment and...
Read More
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.